Concepedia

Danièle Ouellet

DO

Statistics

Publications

59

Citations

10.6K

H-Index

33

Active since

1987

Affiliations

GlaxoSmithKline (United States)(Current)

Research Triangle Park Foundation

Janssen (United States)

Pfizer (United States)

Janssen (Belgium)

Danièle Ouellet is an author at GlaxoSmithKline (United States) specializing in pharmacology, medicine, and pharmacokinetics.

ORCID

Publications per year

1987–2023

59

Publications

59

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

Keith T. Flaherty, J. Infante, Adil Daud et al. · New England Journal of Medicine · 2012 · 2.8K citations · Full text

, , +16

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

Keith T. Flaherty, Caroline Robert, Peter Hersey et al. · New England Journal of Medicine · 2012 · 2.1K citations · Full text

, , +17

Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

Georgina V. Long, Daniil Stroyakovskiy, Helen Gogas et al. · New England Journal of Medicine · 2014 · 1.9K citations · Full text

, , +14

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial

Gerald S. Falchook, Georgina V. Long, Razelle Kurzrock et al. · The Lancet · 2012 · 933 citations · Full text

, , +12

Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic <i>BRAF</i> -Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor

Kevin B. Kim, Richard Kefford, Anna C. Pavlick et al. · Journal of Clinical Oncology · 2012 · 477 citations · Full text

, , +17

1–5 of 59